Justin Kao

Justin is a Partner at DFJ Growth. He focuses on backing founders at the intersection of AI, healthcare, biology, robotics and physical AI, advanced manufacturing, chemistry, and the other hard sciences. Prior to DFJ Growth, Justin co-founded Helix, a leading genomics company, serving as founding CEO and later as chief business officer. Justin led the company’s partnerships with health systems, payers, and life sciences companies, and played a pivotal role in the company’s COVID-19 efforts, where Helix scaled to a large provider of diagnostic testing and viral surveillance. He was also a partner with Khosla Ventures and an investor at Warburg Pincus. Justin started his career at the Boston Consulting Group and also spent time at Onyx Pharmaceuticals, where he played a key role in the acquisition of Proteolix. Justin holds a BS in chemical engineering (with distinction) and an MS in bioengineering from Stanford University. He also received a JD from Stanford Law School and an MBA from Stanford Graduate School of Business, where he was an Arjay Miller Scholar.